In a move that speaks to the pharmaceutical industry's conviction that weight-loss medicine has become a permanent fixture of modern healthcare, Eli Lilly is committing $6.5 billion to a new Houston manufacturing facility dedicated to its oral GLP-1 drug, Foundayo. The plant, set to open in 2030, reflects not merely corporate ambition but a broader cultural reckoning with obesity as a treatable condition rather than a personal failing. With one in three new GLP-1 pill patients reportedly choosing Foundayo, Lilly is positioning itself as a long-term steward of a market that shows no signs of re